Areduction in the number of falls that multiple sclerosis patients experience could someday be among the outcomes of the University of Vermont’s participation in Medidata’s Sensor Cloud Network.
“We are leveraging the tools and technology available in the Medidata Sensor Cloud Network to advance and accelerate our work in the development of fall risk detection algorithms in the multiple sclerosis population, a disease that affects 2.3 million patients worldwide, 50% of whom will experience a fall that negatively impacts their quality of life,” said Ryan McGinnis, director of UVM’s M-Sense Research Group, which develops innovative health technologies with partners in engineering, medicine, mental health and movement science.
UVM, along with eight other highly innovative organizations, is joining the Sensor Cloud Network as part of Medidata’s rapidly expanding approach to patient care. Medidata, a Dassault Systèmes company, has announced that AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont are now part of the first cross-sector collaboration focused on solving the challenges related to sensor integrations, standardization of sensor data, and the development of novel digital biomarkers and algorithms. These will help to create new digital endpoints that could translate into more effective treatments and better healthcare for patients.
Photo: Bailey Beltramo
Fall risk detection is just one of many potential applications. As one of the health technology innovators involved in the network, UVM is at the forefront of revolutionizing patient care and positive outcomes. The University has emerged as a leader in biomedical research in recent years, through its ABET-accredited Biomedical Engineering program, which is unique in its field because of its proximity to the University of Vermont Medical Center (UVMMC), and the launching of its vibrant Center for Biomedical Innovation. Through its work with the Sensor Cloud Network, UVM builds upon its groundbreaking research in the biomedical arena.
The Sensor Cloud Network, which includes contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academic institutions, creates opportunities for data scientists to refine, test and deliver physiological algorithms with clinical meaning at scale. Examples include refined motion parameters like gait, cardiovascular metrics, metabolic insights, and clinical grade speech analytics.
“The Sensor Cloud Network is allowing us to explore the combination of patient reported outcomes and medical grade wearables data in remote settings at scale to better understand this problem and to develop a digital intervention,” McGinnis said. McGinnis is an associate professor in the Department of Electrical and Biomedical Engineering in UVM’s College of Engineering and Mathematical Sciences.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. “As the use of sensors in clinical trials is predicted to reach 50% by 20251, we are focused on making Medidata Sensor Cloud the industry standard for collecting and analyzing medical grade sensor data,” said Ben Schlatka, vice president, Digital Biomarker Solutions at Medidata. “We are excited to work with a diverse group of partners to help shape the future of patient data collection and analysis, and make Sensor Cloud the platform of choice for developing new digital biomarkers across a wide variety of therapeutic areas.”
***
1. Y. Jansen and G. Thornton, “Wearables & Big Data In Clinical Trials — Where Do We Stand?,” Clinical Leader, February 2020. https://www.clinicalleader.com/doc/wearables-big-data-in-clinical-trials-where-do-we-stand-0001
Original source can be found here